Clinical trials Below are current clinical trials.552 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. Detection of Mutant Circulating Tumor (CT)Dna in Uveal Melanoma With Development of a Droplet Digital Pcr (Ddpcr) Assay Rochester, Minn. The purpose of this study is to design, develop and assess the performance characteristics of a ddPCR assay for the detection of mutations associated with uveal melanoma. The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation results obtained for the ddPCR assay on blood to those obtained on paired paraffin embedded tumors. Long-term Follow Up of Patients Previously Enrolled in MC1137 (BEAUTY) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to extend the follow up on the BEAUTY study (MC1137) cohort and collect additional blood samples to evaluate for minimal residual disease and tissue at the time of any breast cancer recurrence. GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate whether CAN-2409 + prodrug added to standard of care immune checkpoint inhibitor (ICI) therapy will be safe and improve the outcome for Non-small Cell Lung Cancer (NSCLC) patients that have stable disease or readiographic progression after at least 18 weeks of ICI therapy or that have refractory disease after at least 9 weeks of ICI therapy. Cell Saver During Tumor Resection Rochester, Minn. The aims of this study are to investigate the presence of tumor cells after filtration of autologous blood products by intraoperative cell saver, and to demonstrate the feasibility of intraoperative blood salvage during intralesional tumor resection. Intraoperative blood salvage is a relatively safe and cost-effective alternative to allogeneic blood transfusion during procedures with large volume blood loss. Salvaged blood products are washed and filtered before reinfusion into the patient. Given the theoretical risk of systemically re-infusing samples contaminated with tumor cells, many surgeons refrain from using intraoperative blood salvage. Aside from a few small studies, there is a paucity of data on the ability of leukocyte reduction filters to remove tumor cells from salvaged blood products. Additionally, no studies to date have investigated this during intralesional tumor resections. Breast MR Rochester, Minn. The purpose of this study is to examine the capability of contrast enhanced breast PCD-CT in staging breast cancer within the breasts and regional nodes of human subjects. Developing and using a PCD-CT imaging technique and postprocessing algorithms, dedicated for breast cancer detection. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas Rochester, Minn., Jacksonville, Fla. This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary goal of this study is to determine the impact of standard of care therapies for TCR MM, in a real-world setting, on patient-reported symptoms, functioning, and QoL, measured prospectively using questionnaires. The secondary goal is to asses clinical endopoints associated with standard of care therapies for TCR MM, in a real-world setting during 12 months of observation. Genomic and Proteomic Analyses of Aggressive Tumors Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to use genomic and proteomic analyses to identify possible diagnostic markers and potential drugs for diagnosing and treating aggressive tumor types or neoplastic processes. Genomic analyses mean looking at the genome, or all the DNA in a cell (DNA is a material in your body that is a genetic map or code that provides instructions that make up your genes). Proteomic analyses mean looking at the proteome, or all the proteins expressed, or made, by DNA at a specific moment in time Tumor Molecular Analysis Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop preclinical models that include cell lines and patient derived xenografts (PDX) that include molecular characterization and testing novel therapies in these preclinical models. Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models have not been cross contaminated during the development process with other ongoing lines. Tissue microarray and immunohistochemical (IHC) analysis will also be performed on cell lines, PDX and patient tissues to identify potential molecular targets for therapy. For patients who consented, patient clinical therapy response data may be correlated with preclinical response data in cell lines and PDX models. A Study to Evaluate Yttrium-90 Therapy for Radiation Lobectomy Jacksonville, Fla. The Patient Group 1 primary objective is to measure the distribution of 90Y glass microspheres throughout the tumor and non-tumor hepatic parenchyma, as assessed by same day postradioembolization study-specific non-FDG PET/CT scan. Correlate this measurement with mean lobar absorbed radiation dose and embolic load given to patients and time taken to achieve adequate Future Liver Remnant (> 40% of total liver volume) to determine if there is an optimal lobar dose and embolic load. The Patient Group 2 primary objectives are to assess the association of circulating and imaging biomarkers on Future Liver Remnant hypertrophy, and to assess progression-free survival between patients with HCC who underwent resection following Y-90 radioembolization with optimal dose and those who presented with an adequate Future Liver Remnant for resection (i.e., who were not treated pre-surgically). Pagination Clinical studies PrevPrevious Page Go to page 4343 Go to page 4444 Go to page 4545 Go to page 4646 Go to page 4747 NextNext Page Request an appointment Expertise & rankingsResearch May 09, 2023 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation for 2023-2024 by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 departments-centers Oncology (Medical)